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Abstract: Boron nitride nanotubes (BNNTs) have generated considerable interest within the 
scientific community by virtue of their unique physical properties, which can be exploited 
in the biomedical field. In the present in vitro study, we investigated the interactions of 
poly-l-lysine-coated BNNTs with C2C12 cells, as a model of muscle cells, in terms of 
cytocompatibility and BNNT internalization. The latter was performed using both confocal 
and transmission electron microscopy. Finally, we investigated myoblast differentiation in the 
presence of BNNTs, evaluating the protein synthesis of differentiating cells, myotube formation, 
and expression of some constitutive myoblastic markers, such as MyoD and Cx43, by reverse 
transcription – polymerase chain reaction and Western blot analysis. We demonstrated that 
BNNTs are highly internalized by C2C12 cells, with neither adversely affecting C2C12 myoblast 
viability nor significantly interfering with myotube formation.
Keywords: boron nitride nanotubes, C2C12 cells, cytocompatibility, up-take, differentiation, 
MyoD, connexin 43
Introduction
Boron nitride nanotubes (BNNTs)1,2 are of significant interest to the scientific 
community. As with carbon nanotubes (CNTs), they have attracted wide attention 
because of their unique and important properties for structural and electronic 
applications.3,4 Despite their structural similarity, carbon and boron nitride nanotubes 
have many different properties. While both BNNTs and CNTs possess a very high 
Young’s modulus, BNNTs exhibit chemical and thermal stability superior to CNTs.5–7 
They also have a constant band gap (ie, an energy difference between the top of the 
valence band and the bottom of the conduction band) of about 5.5 eV:8,9 in contrast, 
CNTs vary from semi-conducting to conducting behavior, depending on their chirality 
and diameter.
Recent investigations have confirmed that BNNTs have excellent piezoelectric 
properties. Ab initio calculations of the spontaneous polarization and piezoelectric 
properties of BNNTs have demonstrated that they function as excellent piezoelectric 
systems with response values larger than those of piezoelectric polymers, and compa-
rable to those exhibited by wurtzite semiconductors.10 Moreover, Bai and colleagues 
have recently experimentally verified a deformation-driven electrical transport and 
the first signs of piezoelectric behavior in multiwalled BNNTs.11International Journal of Nanomedicine 2010:5 286
Ciofani et al  Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
These properties make BNNTs potentially attractive 
candidates for a wide range of applications in the nano 
domain.12 In recent years, several applications of CNTs in the 
field of biotechnology have been proposed,13 but the biomedical 
applications of BNNTs remain largely unexplored.14 Zhi and 
colleagues investigated the interaction between BNNTs and 
various protein species15 and between BNNTs and DNA,16 
but the first studies of the interactions between BNNTs and 
living cells were performed by the authors.17–19 Despite these 
preliminary and interesting observations, it is mandatory to 
extend biological investigations to many different cell types 
and, eventually, in vivo, in order to highlight different behaviors 
following the treatment with BNNTs. As a matter of fact, in our 
experience, distinct cell types treated in vitro with BNNTs may 
respond with different dose sensitivity. Nanovector platforms 
are particularly complex systems that can lead to opposite 
phenomena up to the analyzed in vitro model.
In the present report, we focused our study on up-take, 
cytocompatibility, and differentiation of C2C12 cells, as a 
model of muscle cells, in presence of BNNTs. To perform 
such investigations, stable dispersions of BNNTs were 
prepared using a positively charged protein (poly-l-lysine 
[PLL]) as dispersion agent. PLL-coated BNNTs were also 
conjugated with fluorescent molecules (quantum dots) to 
enable their tracking in living cells.
Due to the piezoelectricity owned by BNNTs, a positive 
interaction between muscle cells and BNNTs would poten-
tially allow their employment in the future, as intracellular 
nanotransducers conveying mechanoelectric stimulation to 
sensitive cells, such as myoblasts. This report lays the basic 
foundations for this challenge. BNNT cytocompatibility 
was investigated in order to identify the highest working 
concentration potentially usable in vitro without affecting cell 
viability; cellular up-take of BNNTs was then studied; finally, 
myogenic differentiative capability retained by C2C12 cells 
internalizing BNNTs was analyzed.
Materials and methods
BNNT dispersion and characterization
BNNTs (provided by the Australian National University, 
Canberra, Australia) were produced by using a ball milling 
and annealing method.20 Details of sample purity and 
composition, as provided by the supplier, include: yield 
80%, boron nitride 97 wt%, metal catalysts (Fe and Cr 
derived from the milling process) ∼1.5 wt% and absorbed 
O2 ∼1.5 wt%.
PLL (81339, MW 70,000–150,000; Fluka, St. Louis, 
MO) was used for the dispersion and stabilization 
of BNNTs. Dispersions were prepared with phosphate-buffered 
solution (PBS). BNNTs (5 mg) were mixed with 10 mL of 
a 0.1% PLL solution in a polystyrene tube. The samples 
were sonicated for 12 h (by a Bransonic sonicator 2510; 
Bransonic, Danbury, CT) using an output power of 20 W for 
all the experiments. After sonication, they were centrifuged 
at 1,100 g for 10 min to remove nondispersed residuals and 
impurities. Excess PLL was removed by ultracentrifugation 
three times at 30,000 g for 30 min at 4°C (Allegra 64R; 
Beckman Coulter, Fullerton, CA) resulting in a stable 
PLL-BNNT dispersion by the noncovalent coating of the 
nanotube walls with PLL. The concentration of BNNTs was 
quantified by spectrophotometric analysis, using a LIBRA 
S12 Spectrophotometer UV/Vis/NIR (Biochrom, Cambridge, 
UK) as previously reported,17 while the residual concentration 
of PLL in the dispersions was assessed using the bicinchoninic 
acid (BCA) method (for details see below: Quantitative 
studies on differentiated C2C12 cells: double stranded 
(ds)-DNA and protein quantification). Microphotographs of 
the final dispersion of BNNTs were obtained with a Zeiss 902 
transmission electron microscope (Carl Zeiss, Oberkochen, 
Germany), dropping a small quantity of aqueous suspension 
on a copper grid.
PLL-BNNTs were covalently labeled with carboxyl 
derivatized quantum dots for cellular tracking studies. 
Carboxyl quantum dots were supplied by Invitrogen (Qdot® 
605 ITK™; Invitrogen, Carlsbad, CA). The conjugation 
reaction between the amino-groups of PLL and carboxylic-
groups of quantum dots was carried out as specified by the 
supplier. Briefly, 4 mL of PLL-BNNT (100 µg/mL) were 
mixed with 8 µL of Qdots (8 µM) and 150 µL of 1-ethyl-
3-(3-dimethylamino-propyl) carbodiimide (10 mg/mL,   
EDC, 03450; Fluka) as activator. The solution was gently 
stirred for 90 min at room temperature for optimal con-
jugation and finally centrifuged (10 min at 1,100 g) to 
remove large aggregates. Finally, ultracentrifugation (twice 
at 30,000 g for 30 min at 4°C) was performed to remove 
unbound quantum dots from the labeled BNNT dispersions. 
Qdot labeled BNNTs were exploited only for confocal 
investigation of the up-take: all other tests (transmission 
electron microscopy [TEM] analysis, cytocompatibility, 
differentiation) were performed on PLL-BNNTs in order to 
avoid any misinterpretation of the data due to the presence 
of Qdots on the nanotubes.
Sample size distribution was analyzed with an N4plus 
submicron particle size analyzer (Beckman Coulter); 
Z-potential measurement was performed with a Nano Z-Sizer 
(Malvern Instruments, Westborough, MA). Each acquisition International Journal of Nanomedicine 2010:5 287
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was performed in triplicate on aqueous nanotube suspensions 
at a concentration of 1 µg/mL.
Cell culture and BNNT tracking
C2C12 mouse myoblasts (ATCC CRL-1772) were cultured 
in expansion medium, constituted by Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 100 IU/mL penicillin, 100 µg/mL 
streptomycin and 2 mM l-glutamine. Cells were maintained 
in normal culture conditions (37°C, saturated humidity 
atmosphere at 95% air/5% CO2). This cell line, widely used as 
muscle cell model,21 can differentiate rapidly, in appropriate 
culture conditions, also forming contractile myotubes that 
produce characteristic muscle proteins.22 In our studies, 
differentiation of C2C12 myoblasts in myotubes was induced 
by switching, in cell specimens at 80%–90% confluence, the 
culture medium from expansion to differentiation medium, 
composed of DMEM supplemented with 2 mM l-glutamine, 
100 IU/mL penicillin, 100 µg/mL streptomycin, 1% Insulin-
Transferrin-Selenium ([ITS] I3146; Sigma, St. Louis, MO), 
and 1% FBS.
Cell internalization studies were performed by both 
confocal and transmission electron microscopy.
To pursue confocal analysis, 5,000 cells were seeded 
on coverglasses (of 1.2 cm diameter), and cultured for 
3 days. Qdot labeled-BNNTs were then added to the 
culture medium with a final concentration of 5 µg/mL of 
PLL-BNNTs and incubated with the cells for 12 h. Calcein 
AM (2 µM; Molecular Probes, Eugene, OR) was used for 
cell cytoplasm labeling (green fluorescence), while 5 µg/mL 
of Hoechst 33342 (H1399; Invitrogen) was used for nucleus 
staining (blue). Confocal analysis was finally carried out 
using a Nikon Inverted Microscope TiE equipped with a 
Nikon Confocal Laser System A1Rsi (software for image 
analysis was NIS Elements C 3.06; Nikon Instruments, 
Melville, NY).
Tests using sodium azide ([NaN3] 478484; Carlo Erba, 
Milan, Italy), a well known endocytosis inhibitor, enabled 
investigation of the mechanism responsible for internalization 
of the BNNTs.23 NaN3 acts by blocking production of 
adenosine triphosphate (ATP) in cells and thus the energy 
required for the endocytotic pathway. The cell culture was 
treated for 30 min with 10 mM NaN3-modified medium and 
then incubated for 3 h in culture medium containing 5 µg/mL 
of Qdot labeled BNNTs. Confocal analysis followed as previ-
ously described.
Internalization was also investigated by TEM. C2C12 cells 
were seeded at 106 cells/T25 flask. After attachment, cells 
were incubated in a PLL-BNNT modified medium (at a final 
concentration of 5 µg/mL). After 12 h of incubation, samples 
were washed in PBS 0.1 M and thereafter fixed when still 
adherent to flasks with 1% w/v glutaraldehyde–4% w/v 
paraformaldehyde in PBS 0.1 M pH 7.2 for 2 h at 4°C. After 
washing, the cells were detached by scraping, post-fixed 
in 1% w/v OsO4 PBS 0.1 M pH 7.2 for 1 h, washed and 
dehydrated with acidified aceton-dimethylacetal (Fluka) for 
10 min. Thus, the samples were mixed in Epon-Durcupan 
resin in BEEM capsules #00 (Structure Probe, West Chester, 
PA) overnight at room temperature and finally embedded in 
resin at 56°C for 48 h. Ultra-thin sections (20–30 nm thick) 
were obtained with an Ultrotome Nova ultramicrotome 
(LKB, Bromma, Sweden) equipped with a diamond knife 
(Diatome, Biel/Bienne, Switzerland).
The sections were placed on 200 square mesh nickel grids, 
counterstained with saturated aqueous uranyl acetate and lead 
citrate solutions and observed in a Zeiss 902 transmission 
electron microscope (Carl Zeiss).
Cytocompatibility assays
Both quantitative (Trypan Blue, MTT) and qualitative 
(LIVE/DEAD®, annexin V-FITC) assays were performed 
in order to assess cytocompatibility of BNNTs with 
C2C12 cells and to establish the maximum working 
concentration to use.
Cells (250,000 in T25 flasks) were incubated for 24, 
48, and 72 h in standard culture conditions to determine 
their viability following incubation with PLL-BNNT modi-
fied media, at various concentrations: 0 (k-, as control), 
5, 10, and 15 µg/mL of BNNTs. A further control test 
using 3 µg/mL of PLL was performed, corresponding to 
the concentration detected in the dispersion of 15 µg/mL of 
PLL-BNNTs. The number of viable cells was estimated with 
Trypan Blue exclusion (T0887; Sigma). Briefly, cell mono-
layers were rinsed twice with PBS and re-suspended with 
trypsin and EDTA. An aliquot of the cells was immediately 
stained with 0.4% Trypan Blue, and the number of viable 
cells was determined using a hemocytometer and light 
microscopy.
For  metabolic  activity  testing,  MTT  (3-(4.5-
dimethylthiazole-2-yl)-2.5-diphenyl tetrazolium bromide, 
M2128; Sigma) assay was carried out after 24, 48, and 72 h 
of incubation with PLL-BNNT modified media. After Trypan 
Blue counting, 30,000 viable cells were seeded in 96-well 
plate chambers (n = 6). Once complete cell adhesion has been 
verified (about 6 h after seeding), cells were incubated with 
MTT 0.5 mg/mL for 4 h. The supernatant was then removed International Journal of Nanomedicine 2010:5 288
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and the cell samples were treated with 100 µL of dimethyl 
sulfoxide ([DMSO], D8418; Sigma). The absorbance at 
570 nm was measured with a VERSAMax microplate 
reader (Molecular Devices). A reference control test (k-) 
was included.
Viability was further investigated with the LIVE/DEAD® 
viability/cytotoxicity Kit (Molecular Probes). The kit 
contains Calcein AM (4 mM in anhydrous DMSO) and 
ethidium homodimer-1 [EthD-1, 2 mM in DMSO/H2O 1:4 
(v/v)]. After incubation for 24, 48, and 72 h at different 
PLL-BNNT concentrations (0, 5, 10, and 15 µg/mL), cells 
(20,000 in 24-well plate chambers, n = 3) were rinsed with 
PBS and treated for 10 min at 37°C with 2 µM calcein AM 
and 4 µM EthD-1 in PBS. A further control with 3 µg/mL 
of PLL alone was performed. Cells were finally observed 
with an inverted fluorescence microscope (TE2000U; Nikon 
Instruments) equipped with a cooled CCD camera (DS-5MC 
USB2l; Nikon Instruments) and with NIS Elements imaging 
software (Nikon Instruments) equipped with the appropriate 
filters.
For early apoptosis detection, 20,000 cells were seeded 
in 24-well plate chambers (n = 3) and treated with 0, 5, 10, 
and 15 µg/mL of PLL-BNNTs for 24 h. A further control 
with 3 µg/mL of PLL alone was performed. ApoAlert Kit 
(Clontech Laboratories, Mountain View, CA) was used 
to evaluate differences between normal and apoptotic 
cells after treatments. The kit contains annexin V-FITC 
(20 µg/mL in Tris-NaCl), 1× binding buffer and propidium 
iodide (50 µg/mL in 1× binding buffer). Cells were rinsed 
with 1× binding buffer and then incubated with 200 µL of 
1× binding buffer containing 5 µL of the annexin V solution 
and 10 µL of the propidium iodide solution. After incubation 
in the dark at room temperature for 20 min, cells were 
examined by fluorescence microscopy with the appropriate 
filters.
Quantitative studies on differentiated 
C2C12 cells: Double stranded (ds)-DNA 
and protein quantification
To perform value normalization, both ds-DNA and total 
protein content assays were carried out in cascade on the 
same samples after cell lysis. Proteic production was here 
investigated as an index of cell synthesis compatible, although 
not specific, with the differentiation process.
For ds-DNA and protein quantifications on differentiated 
C2C12, 150,000 cells were seeded in 6-well plate cham-
bers and when 90% of confluence was reached, the growth 
medium was changed to the differentiating medium. 
All assays (n = 3) were performed following 3 days of 
incubation with differentiating medium loaded with 0   
(control cultures), 5 and 10 µg/mL of PLL-BNNTs. 
Moreover, individual samples were run in triplicate to 
minimize operator error.
At the endpoint, the culture medium was removed 
from the cell samples and double distilled (dd)-H2O was 
added; the samples were frozen at -20°C and stored for 
subsequent assays. Cell lysates were thus obtained by two 
freeze/thaw cycles of the samples: overnight freezing at 
-20°C, 10 min thawing at 37°C in a water bath with stirring 
for 15 s to enable both the ds-DNA and the proteins to go 
into solution.
Ds-DNA content in cell lysates was measured using the 
PicoGreen kit (Molecular Probes24). The PicoGreen dye 
binds to ds-DNA and the resulting fluorescence intensity 
is directly proportional to the ds-DNA concentration 
in solution. Standard solutions of DNA in ddH2O at 
concentrations ranging from 0–6 µg/mL were prepared and 
50 µL of standard or sample was loaded for quantification in 
a 96-well black microplate. Working buffer and PicoGreen 
dye solution were prepared according to the manufacturer’s 
instructions and 100 and 150 µL/well added, respectively. 
After a 10 min incubation in the dark at room temperature, 
fluorescence intensity was measured on a plate reader 
(Victor3; PerkinElmer, Waltham, MA) using an excitation 
wavelength of 485 nm and an emission wavelength of 
535 nm.
Total protein concentration was determined by the BCA 
method (Pierce Biotechnology, Rockford, IL25) following the 
microplate procedure. Cell lysates and working reagent were 
loaded inside a 96-well microplate at 25 and 200 µL/well, 
respectively. The microplate was gently shaken and then 
incubated at 37°C for 30 min. Samples were cooled down 
to room temperature and absorbance was read at 562 nm on 
a plate reader (BioRad Laboratories, Hercules, CA). Protein 
concentration of cellular specimens was then obtained by 
reference to bovine serum albumin (BSA) standards. Finally, 
total protein content was normalized by DNA content as 
determined by the PicoGreen assay.
Additionally, cell morphology observation by inverted 
light microscopy on hematoxylin–eosin (H&E) stained 
specimens was carried out on cell samples analogous to the 
ones previously described. Briefly, samples were fixed with 
1% buffered formalin at 4°C for 10 min, stained with for 5 s 
with hematoxylin, rinsed in tap water for 5 s, stained with 
eosin for 1 s, washed in tap and distilled water, and finally 
dried at room temperature.International Journal of Nanomedicine 2010:5 289
Interactions between poly-L-lysine-coated boron nitride nanotubes and C2C12 cells Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Formation of multinucleated myoutubes was assessed 
with Hoechst staining and observation with fluorescence 
microscope. Grade of differentiation was quantitatively 
evaluated calculating the fusion index of the cultures, 
determined by dividing the total number of nuclei in myotubes 
(2 nuclei) by the total number of nuclei counted.26 More 
than 30 myotubes were analyzed for each assay (experiments 
performed in triplicate).
Reverse transcription-polymerase chain 
reaction (RT-PCR) for detection of  
MyoD and connexin 43 (Cx43) mRNA  
in differentiated C2C12 cells
C2C12 cells were cultured as described in the previous sec-
tion. Assays were performed after 3 days of incubation with 
standard differentiating medium (control cultures) followed 
by 3 days of differentiating medium, containing either 0, 5, 
or 10 µg/mL of PLL-BNNTs.
Total RNA was isolated from cell cultures using High 
Pure RNA Isolation kit (Roche, Basel, Switzerland) 
according to the manufacturer’s protocol. RNA concentration 
was measured in a spectrophotometer at 260 nm. Identical 
amounts of RNA were reverse transcribed into cDNA using 
the Transcriptor First Strand cDNA Synthesis kit (Roche). 
Treatment with DNase I (Invitrogen) was performed 
following the manufacturer’s indications. Subsequently, 
cDNA was amplified by PCR with the specific primers 
and procedures listed in Table 1. The housekeeping gene, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was 
used as internal standard. Each RT-PCR was performed at 
least twice. The PCR products were loaded on a 2.5% agarose 
gel and stained with ethidium bromide.
Gel electrophoresis and Western 
blot for MyoD and Cx43 detection 
in differentiated C2C12 cells and 
immunocytochemistry for MyoD
C2C12 pellets obtained from control cultures and cultures 
treated with 0, 5 and 10 µg/ml of PLL-BNNTs (see previous 
Section for details) were washed in Dulbecco’s modified 
phosphate saline buffer (D-PBS; Sigma Aldrich), resus-
pended in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 2 mM EDTA, 1% NP-40, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 2 µg/mL Aprotinin, 2 µg/mL Pepstatin, 
10 µM Leupeptin, 200 µM NaVO3 and 200 µM NaF) and 
incubated for 30 min in an ice bath, vortexing every 10 min. 
Cell lysates were then centrifuged at 15,000 rpm for 20 min at 
4°C, supernatants were recovered and protein concentration 
was determined for all the samples using the BCA method.
Proteins (30 . µg) from the supernatant were separated 
on a 10% polyacrylamide gel under reducing conditions, 
transferred to a polyvinyilidene fluoride (PVDF) membrane 
(Immobilon-P; Millipore, Bedford, MA) and probed with 
either mouse monoclonal anti-MyoD antibody (Santa Cruz, 
Santa Cruz, CA), or with mouse monoclonal anti-connexin 43 
(Santa Cruz), or with mouse monoclonal anti-β-actin (Sigma 
Aldrich) as internal control of the total protein content. SNAP 
i.d. system (Millipore) was used to probe PVDF membranes. 
Briefly, PVDF membranes were placed in the device holders, 
saturated in 0.1% Tween Tris-buffered saline (T-TBS) 
containing 0.25% dry fat-free milk (immediately eliminated 
by vacuum application) and incubated for 10 min with 
either anti-MyoD (1:100 in T-TBS), or anti-Cx43 (1:10,000 
in T-TBS), or anti-β-actin (1:2,000 in T-TBS) antibodies, 
respectively. After three washings in T-TBS under vacuum 
application, the membranes were incubated with goat 
anti-mouse immunoglobulin-horseradish peroxidase 
conjugate (KPL, 1:2,000 in T-TBS). Five washings with 
T-TBS were performed (under vacuum application) and the 
immunocomplexes were then detected on PVDF membranes 
by chemiluminescence (ECL Turbo; Euroclone, Milan, Italy) 
according to the manufacturer’s instructions.
For immunocytochemical analysis of MyoD, C2C12 
were seeded at a cell density of 104 cells/well onto chamber 
slides and cultured either with or without BNNT (5 µg/mL). 
Thereafter, the cells were fixed with 1% buffered formalin 
in PBS for 10 minutes at 4°C and then washed in PBS. 
MyoD antigen retrieval was performed in citrate buf-
fer pH 6.0 (Diapath, Bergamo, Italy) with microwaves 
(6 × 5 min at 600 W). Aspecific antibody binding sites 
Table 1 Primer sequences and conditions for RT-PCR analysis
Gene Sequence Size  
(bp)
Cycle
GAPDH 5′-AGAACATCATCCCTGCATCC-3′ 
5′-CCTGCTTCACCACCTTCTTG-3′
183
35 cycles: 
30 sec, 94°C 
30 sec, 54°C 
30 sec, 72°C
MyoD 5′-TTCTATGACGACCCGTGTTT-3′ 
5′-GGCCTCATTTACTTTGCTCA-3′
300
35 cycles: 
45 sec, 94°C 
45 sec, 54°C 
45 sec, 72°C
Cx43 5′-GCGCAGAGCAAAATCGAA-3′ 
5′-AATCTCCAGGTCATCAGG-3′
206
35 cycles: 
60 sec, 95°C 
30 sec, 55°C 
30 sec, 72°C
Abbreviation: RT-PCR, reverse transcription–polymerase chain reaction.International Journal of Nanomedicine 2010:5 290
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were saturated by normal goat serum (Vector Laboratories, 
Burlingame, CA) 1:20 in PBS (for 20 min at 37°C); the cells 
were then incubated overnight at 4°C either with the specific 
anti-MyoD antibody (1:50 PBS containing 0.1% BSA) or 
without primary antibody, as negative control.
MyoD antibody binding was revealed using the ABC kit 
(Vector Laboratories) and diaminobenzidine (DAB; GeneTex, 
San Antonio, TX) as chromogen substrate. Moreover, the 
cells were counterstained by hematoxylin and subsequently 
dehydrated in a graded series of ethanol, clarified with xylene 
and mounted with DPX balsam. The samples were observed 
by an optical microscope.
Statistical analysis
Analysis of the data was performed by analysis of variance 
(ANOVA) followed by Student’s t-test to test for significance, 
which was set at 5%. MTT tests were performed in exaplicate; 
all the other assays in triplicate. In all cases, three independent 
experiments were carried out. Results are presented as mean 
value ± standard error of the mean (SEM).
Results and discussion
Interactions between C2C12 cells and 
BNNTs
Stable dispersions of BNNTs were obtained by means of 
PLL as a dispersion agent. PLL is a cytocompatible polymer 
with positive amino-terminal groups. Figure 1 shows a 
TEM image of a 200 µg/mL dispersion after preparation: 
both single nanotubes (red arrows) and small aggregates of 
nanotubes are visible, with a size congruent to the results 
achieved with the dynamic light scattering analysis, that 
yielded an average particle value of 242 ± 92 nm. Moreover, 
Z-potential analysis revealed a strong positive Z-potential 
(43.40 ± 3.26 mV), highlighting the high stability of the 
dispersions. After the preparation procedure, the residual PLL 
concentration, evaluated with the BCA method, resulted to 
be about 1:5 w/w with respect to that of the BNNTs present 
in the dispersion (ie, for a dispersion containing 15 µg/mL of 
BNNTs, residual PLL concentration was about 3 µg/mL).
Figure 2 shows the results of the internalization assays 
performed with confocal microscopy. Figure 2a depicts 
consecutive slides of cells (magnification 60X, z-stack step 
500 nm) following incubation with BNNTs, showing Qdot-
labelled BNNTs (red) strongly internalized in the cell cyto-
plasm (green). No evidence of BNNTs in the nuclei (blue) 
of cells was observed.
These observations demonstrated that PLL-BNNTs were 
internalized by the cells, but provided no information on the 
nature of the mechanism responsible for this up-take. Sodium 
azide was exploited to investigate the energy-dependence of 
the up-take mechanism of PLL-BNNTs. The chosen incu-
bation time was 30 min, as optimal compromise between 
effective ATP blocking by sodium azide, and reduced cyto-
toxic effects resulting from a prolonged energy deficiency. 
Figure 2b shows a confocal image of cells incubated for 1 h 
in a medium containing 5 µg/mL of Qdot-labelled BNNTs: 
internalization occurred as shown in the previous tests. An 
image of C2C12 cells analogously incubated but following 
pre-treatment with sodium azide is shown in Figure 2c. Here 
a clear inhibition of cell up-take was evidenced by a negli-
gible amount of internalized BNNTs and a massive BNNT 
accumulation on the cell membrane. This result demonstrates 
that the internalization of PLL-BNNTs by C2C12 is energy-
dependent, as already noticed for PEI-coated BNNTs in 
other cell lines.18
TEM analysis reported in Figure 3a confirmed that 
PLL-BNNTs are abundantly internalized by C2C12 cells, 
showing the presence of noncellular electron-dense mate-
rial, compatible for appearance and dimensions with BNNTs 
(see Figure 1), in cytoplasmic vacuoles. Arrows are used to 
indicate the vacuoles/vesicles in the intracellular environ-
ment. Figure 3b, as control, shows C2C12 cells cultured in 
the same conditions but without BNNT treatment: absence 
of BNNT-like material in the cytoplasmic compartments 
is evident. Such observations are consistent with those of 
Yehia and colleagues,27 Raffa and colleagues,28 and Tutak 
and colleagues29 performed on carbon nanotubes: in these 
studies different kinds of mammalian cells were exposed 
to CNTs dispersed in cell growth medium that presented 
1 µm
Figure 1 TEM image of PLL-BNNT dispersion: both single nanotubes (red arrows) 
and small aggregates of nanotubes are visible.International Journal of Nanomedicine 2010:5 291
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a
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Figure 2 Confocal analysis of BNNT internalization a) and investigation of its mechanism: BNNT uptake b) and its inhibition after treatment with sodium azide c).International Journal of Nanomedicine 2010:5 292
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a
b
Figure 3 TEM imaging of C2C12 cells incubated for 12 h with (a) and without 
(b) a 10 µg/mL BNNT modified medium. The TEM micrograph shows C2C12 with 
vesicles containing BNNT (arrows) in the treated sample. Magnification 7000×.
Abbreviations: BNNT, boron nitride nanotubes; M, mitochondria; N, nuclei;   
  TEM, transmission electron microscopy.
high-resolution TEM images of dense dark material within 
intracellular vacuoles.
The data concerning the effects of BNNT up-take are 
reported in Figure 4.
Viability assays show that after 24, 48, and 72 h of 
incubation at different PLL-BNNT concentrations (5, 10, and 
15 µg/mL), cell densities did not differ from their respective 
controls. In all cases, preliminary cell viability assessed 
with Trypan Blue was greater than 90%. The data at 72 h 
confirmed that BNNTs did not affect cellular replication: the 
cells reached confluence in each test, undergoing almost three 
complete replication cycles. The same considerations are valid 
for controls performed with 3 µg/mL of PLL, ie, the amount 
of PLL present in the highest concentrated BNNT sample.
Figure 4 shows MTT results for each test. C2C12 
exhibited a slight decrease in metabolic activity following 
incubation with PLL-BNNTs. Cells incubated with 5 µg/mL 
of nanotubes sustained a decrease of about 10% after 24, 
48, and 72 h of incubation, but all these results were not 
statistically different from the respective controls (in all cases, 
P  0.05). Similar results were obtained by culturing C2C12 
with 10 µg/mL of PLL-BNNTs. Incubation with 15 µg/mL of 
nanotubes provided a nonsignificant MTT reduction after 24 
and 48 h (about 15%; P  0.05), but the decrease in metabolic 
activity became significant (about 20%; P  0.05) by the third 
day. The same trend was followed by cells incubated with 
3 µg/mL of PLL alone (statistical significance after 3 days of 
incubation), thus demonstrating that, at these concentrations, 
the slight cytotoxicity is mainly due to the surfactant rather 
than to a negative effect of the nanotubes.
On the basis of these results, we decided to use 5 and 
10 µg/mL as the working concentrations for the subsequent 
studies.
Optimal cell viability up to 10 µg/mL of BNNTs was 
confirmed by the LIVE/DEAD® viability/cytotoxicity assay. 
Live cells are distinguished by the presence of ubiquitous 
intracellular esterase activity, determined by the enzymatic 
conversion of the nonfluorescent cell-permeant agent, calcein 
AM, to an intensely fluorescent molecule, calcein. Calcein is 
well retained within live cells, producing an intense uniform 
green fluorescence. Conversely, EthD-1 enters cells with 
damaged membranes and undergoes a 40-fold enhance-
ment of fluorescence upon binding to nucleic acids, thereby 
producing a bright red fluorescence in dead cells. EthD-1 is 
excluded by the intact plasma membrane of live cells.
Figure 5 shows the results of the viability/cytotoxicity 
assay, performed after 24, 48, and 72 h of incubation with 
0, 5, 10, and 15 µg/mL of BNNTs. A further test with 
3 µg/mL of PLL alone was also carried out. No evidence 
of cell membrane damage was present following treatment 
of C2C12 cells up to 10 µg/mL of PLL-BNNTs, clearly 
demonstrating optimal cell viability, completely comparable 
to that of the control cells (0 µg/mL). A nonnegligible amount 
of red stained cells was present in the samples treated with 
either 15 µg/mL of PLL-BNNTs or 3 µg/mL of PLL, thus 
confirming the MTT assay quantitative results.
Early apoptotic phenomena were investigated as 
described in Cytocompatibility assays. One of the methods 
employed to study apoptosis detects changes in the 
position of phosphatidylserine (PS) in the cell membrane. 
In nonapoptotic cells, most PS molecules are localized 
on the inner layer of the plasma membrane, but soon International Journal of Nanomedicine 2010:5 293
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after the initiation of apoptosis, PS is redistributed to the 
outer layer of the membrane, and becomes exposed to the 
extracellular environment.30 Exposed PS can be easily 
detected with annexin V, a 35.8 kDa protein with strong 
affinity for PS.
Propidium iodide (PI) is a DNA red fluorescent inter-
calating agent; it is membrane impermeant and generally 
excluded from viable cells. Therefore, it can be used jointly 
with annexin V-FITC to differentiate necrotic (red stained), 
early apoptotic (green stained), apoptotic (green and red 
stained) and normal cells (unstained).
Figure 5 also shows the results of apoptotic assay carried 
out on C2C12 cells incubated for 24 h with 0, 5, 10, and 
15 µg/mL of PLL-BNNTs and a control culture incubated 
with 3 µg/mL of PLL. No evidence of apoptosis was 
observed in all the treatments, with a few dead cells in the 
sample treated with 15 µg/mL of PLL-BNNTs or 3 µg/mL 
of PLL. Such observations are again in agreement with 
the results obtained with the LIVE/DEAD® assay and the 
Trypan Blue test.
Taken together, these findings clearly demonstrate the 
absence of significant negative effects of PLL-BNNTs on 
C2C12 myoblasts up to a concentration of 10 µg/mL.
C2C12 differentiation
Differentiation of C2C12 myoblasts (80%–90% confluent) 
in myotubes was obtained after a 3-day culture of these 
samples under differentiating conditions (1% FBS, 1% ITS). 
Cultures supplemented with PLL-BNNTs were monitored 
and compared to control cultures as previously reported, 
in order to verify whether BNNTs may contrast the 
differentiation process. Proliferation and protein synthesis 
of differentiating myoblasts were assessed after 3 days of 
incubation in differentiating medium supplemented with 
0, 5 and 10 µg/ml of PLL-BNNTs by measuring ds-DNA 
and total protein contents.
Cultures treated with 5 µg/ml of PLL-BNNTs versus 
controls exhibited a nonsignificant drop in ds-DNA amount 
(2%), but corresponding to a more sustained increase in 
protein content (about 15%). Consequently, when normalized 
by ds-DNA (and therefore by cell number), the total proteins 
resulted in a significant rise (about 20%), which was 
statistically different with respect to the control (P  0.05). 
Quantitative results showed that normalized protein content 
is about 92 µg/µg-DNA in BNNT-treated samples, whereas 
it is about 78 µg/µg-DNA in controls. Cultures treated with 
10 µg/mL of PLL-BNNTs versus controls exhibited DNA 
increment (about 10%) and slight protein decrement (about 
3%), resulting in a normalized protein content of about 
70 µg/µg-DNA in BNNT-treated samples, nonsignificantly 
different from the control.
These findings, summarized in Figure 6, confirmed that 
in presence of BNNTs C2C12 cells retained a good protein 
synthesis capacity under differentiating conditions.
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The morphology of differentiating cells was assessed by 
phase contrast microscopy and H&E staining after 3 days of 
culture. Figure 7 shows differentiated C2C12 cultured with 
0 (a), 5 (b), and 10 (c) µg/mL of PLL-BNNTs, demonstrating 
that treated cells developed myotubes without qualitative 
differences from the control cultures.
Quantitative assessment of myotube formation was 
performed evaluating the fusion index of the three different 
cultures (Figure 7d). Also in this case, no statistically 
significant differences were observed between samples 
treated with 0, 5 and 10 µg/mL of BNNTs: in all experiments 
the calculated fusion index was higher than 25% (P  0.5), 
indicating well sustained differentiative processes.
We can therefore conclude that BNNTs showed a 
negligible effect on the proliferation of differentiating C2C12 
myoblasts; moreover, they were found to affect neither the 
cellular protein synthesis nor the qualitative/quantitative 
development of myotubes in vitro.
C2C12 cell differentiation was also investigated throughout 
the expression of some constituent myoblastic markers, such 
as MyoD and Cx43, both at the gene and protein level.
Differentiation of myogenic cells is regulated by multiple 
factors. Among these MyoD is known to play a key role in 
regulating myoblast differentiation. MyoD belongs to a family 
of proteins known as myogenic regulatory factors (MRFs).31 
Some of these bHLH (basic helix loop helix) transcription 
24 h
0 µg/mL
5 µg/mL
10 µg/mL
15 µg/mL
PLL
3 µg/mL
48 h 72 h Apo 24 h
Figure 5 LIVE/DEAD® viability/cytotoxicity assay and early apoptotic detection (annexin V-FITC/PI assay) performed for different incubation times and concentrations.
Note: Scale bar: 100 µm.International Journal of Nanomedicine 2010:5 295
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factors act synergistically, others sequentially in the myogenic 
differentiation cascade. MRF family members include MyoD, 
Myf5, myogenin, and MRF4 (Myf6). MyoD is one of the 
earliest markers of myogenic commitment, being expressed 
in activated satellite cells and in their progenitors.32
Connexins, such as Cx43, are proteins present in the 
myoblasts involved in the formation of gap junctions, composed 
of connexin-based connexons. Such junctions regulate the 
intercellular passage of small molecules, including inorganic 
ions, small metabolites and second messengers, thus achieving 
electrical, as well as metabolic, coupling of the cells.33
Figure 8a shows MyoD and Cx43 mRNA levels in 
differentiated C2C12 cells treated with 0, 5 and 10 µg/mL of 
PLL-BNNTs, as obtained by RT-PCR. These results high-
lighted that the expression of both Cx43 and MyoD genes was 
not drastically affected by the administration of BNNTs at a 
concentration lower than 10 µg/mL: Cx43 and MyoD mRNAs 
were found to be well expressed in all the tested samples.
Western blot analysis fully agrees with the RT-PCR 
results: Figure 8b shows a good synthesis level of both Cx43 
and MyoD proteins for all the tested concentrations. Finally, 
immunocytochemistry highlighted the main nuclear local-
ization of MyoD, with no appreciable difference between 
BNNT-treated and untreated cells. Cytoplasmatic detection 
of MyoD was only visible in mitotic cells.
All together, these results corroborated the findings 
obtained using the fusion index evaluation and the qualitative 
analysis of the myotube morphology reported in Figure 7. 
Therefore, myotube formation resulted to be neither inhibited 
nor delayed by BNNT up-take, indicating that BNNTs in the 
tested range can be compatible with C2C12 differentiation.
Conclusions
In sharp contrast to the applications of CNTs, that have been 
proposed in biotechnology in recent years, the biomedical 
applications of BNNTs have received scant attention 
despite their unique and impressive chemical and physical 
properties. As regards CNTs, a huge amount of data can be 
found in the literature about their biocompatibility,34 often 
with contrasting results, and the possibility of demonstrating 
the safety of these nanomaterials is quite remote. On the 
contrary, a few studies are available for BNNTs, hence the 
importance to pursue rational and systematic investigations 
of the interactions between BNNTs and living matter.
In this paper, we reported on the results of the interaction 
between PLL-coated BNNTs and C2C12 myoblasts, as 
model of skeletal muscle cells. After obtaining a stable 
dispersion of BNNTs based on PLL wrapping, we used 
confocal microscopy and TEM analysis to demonstrate that 
a high internalization of PLL-BNNTs, following an energy-
dependent mechanism, occurred in C2C12 cells. Moreover, 
cytocompatibility assays performed on C2C12 myoblasts 
denoted excellent proliferation and metabolic activity up to a 
concentration of 10 µg/mL of PLL-BNNTs and up to a 72 h 
culture time. At these concentrations, apoptotic, necrotic and 
membrane permeabilisation phenomena were completely 
absent, as demonstrated by both the annexin V-FITC/PI assay 
and the LIVE/DEAD® test. Differentiation of C2C12 cells 
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Figure 7 Light microscopy on H&E-stained cell samples showing myotube formation: differentiated C2C12 cultured with 0 (a), 5 (b), and 10 (c) µg/mL of PLL-BNNTs; fusion 
index evaluated for the three cultures (d).
Abbreviations: BNNTs, boron nitride nanotubes; H&E, hematoxylin–eosin; PLL, poly-l-lysine.International Journal of Nanomedicine 2010:5 297
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Figure 8 RT-PCR results for MyoD and Cx43 expression in C2C12 cells differentiated in presence of 0, 5, and 10 µg/ml of PLL-BNNTs; GAPDH was used as internal standard 
(a) Western blot results for MyoD and Cx43 production in the same cultures; β-actin was used as internal standard (b) Immunocytochemical analysis for MyoD expression 
on BNNT-treated cell samples (c) and controls without BNNTs (d) “Bn” indicates visible dotting in the cytoplasm due to BNNTs, the arrows indicate MyoD positive cells at 
nuclear level, while the arrowhead indicates MyoD positive cells at cytoplasm level.
Abbreviations: BNNTs, boron nitride nanotubes; H&E, hematoxylin–eosin; PLL, poly-l-lysine; RT-PCR, reverse transcription – polymerase chain reaction.
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and formation of myotubes did not prove to be significantly 
affected by incubation with BNNT-modified differentiating 
medium for 72 h. The protein content of the differentiating 
cells was comparable or even superior in treated with respect 
to control cultures; mRNA of constitutive myoblastic mark-
ers, such as MyoD and Cx43, resulted to be still expressed in 
cells treated up to 10 µg/ml of BNNTs. Moreover, Western 
blot analysis showed a similar MyoD and Cx43 synthesis in 
all the treated samples, thus confirming no severe adverse 
effects on C2C12 differentiation.
Collectively, these experimental findings confirm that 
BNNTs are suitable for the development of novel nanovectors 
for biomedical applications. The exploitation of their peculiar 
physical properties, especially piezoelectricity, could in fact 
provide the basis for clinical electrostimulation therapies 
for various cardiac, skeletal and visceral muscular, and 
neurogenic disorders.
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